Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States

J Rheumatol. 2019 Aug;46(8):920-927. doi: 10.3899/jrheum.180445. Epub 2019 Feb 15.

Abstract

Objective: To quantify healthcare resource utilization (HRU), work loss, and annual direct and indirect healthcare costs among patients with systemic sclerosis (SSc) compared to matched controls in the United States.

Methods: Data were obtained from a large US commercial claims database. Patients were ≥ 18 years old at the index date (first SSc diagnosis) and had ≥ 1 SSc diagnosis in the inpatient (IP) or emergency room (ER) setting, or ≥ 2 SSc diagnoses on 2 different dates in the outpatient (OP) setting between January 1, 2005, and March 31, 2015; continuous enrollment was required during the followup period (12 months after the index date). Individuals with no SSc diagnoses were matched 1:1 to patients with SSc. Wilcoxon signed-rank and McNemar tests were used for comparisons and regressions with generalized estimating equations for adjusted OR (aOR) and incidence rate ratios (IRR) between 2 cohorts.

Results: There were 2192 pairs of patients with SSc and matched controls included (mean age 57.6 yrs; 84.3% female); of these, 233 were eligible for work loss/indirect cost analyses. Compared to matched controls, patients with SSc had significantly higher HRU and costs during the 1-year followup period, IP admissions (adjusted IRR = 2.4), IP hospitalization days (adjusted IRR = 3.1), ER visits (adjusted IRR = 2.0), OP visits (adjusted IRR = 2.3), and days of work loss (adjusted IRR = 2.6). The adjusted difference in annual direct and indirect costs was US$12,820 and $3103, respectively (all p < 0.0001).

Conclusion: Patients with SSc had a high direct and indirect economic burden postdiagnosis.

Keywords: DIRECT HEALTHCARE COSTS; HEALTHCARE RESOURCE UTILIZATION; INDIRECT COSTS; SYSTEMIC SCLEROSIS; WORK PRODUCTIVITY LOSS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cost of Illness
  • Female
  • Health Expenditures*
  • Health Resources / economics
  • Hospitalization / economics*
  • Humans
  • Insurance, Health*
  • Male
  • Middle Aged
  • Patient Acceptance of Health Care*
  • Retrospective Studies
  • Scleroderma, Systemic / economics*
  • United States